Metastatic neoplasm
diseaseOn this page
Also known as metastatic diseasemetastatic tumormetastatic tumour
Summary
Metastatic neoplasm (MONDO:0024883) is a cancer and 75 clinical trials. Top therapeutic interventions include donepezil, regorafenib, and adagrasib. A subtype of secondary neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 75
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | metastatic neoplasm |
| Mondo ID | MONDO:0024883 |
| EFO | EFO:0009709 |
| NCIT | C3261 |
| UMLS | C2939420 |
| MedGen | 422476 |
| Is cancer (heuristic) | yes |
Also known as: metastatic disease · metastatic neoplasm · metastatic tumor · metastatic tumour
Disease family
An umbrella term covering 1 Mondo subtype.
Classification path: disease › human disease › disease by etiologic mechanism › cancer or benign tumor › neoplastic disease or syndrome › secondary neoplasm › metastatic neoplasm
Related subtypes (4): Richter transformation, malignant spiradenoma, Pancoast syndrome, secondary malignant neoplasm
Subtypes (1): metastatic malignant neoplasm
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
Drugs indicated for this disease
No approved or late-stage (phase ≥3) drug is indicated for this disease; the following are in earlier-phase trials only.
Earlier-phase candidates (phase 2, investigational — efficacy not yet established): Pembrolizumab.
Clinical trials & evidence
Clinical trials
Clinical trials: 75.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE1 | 25 |
| Not specified | 19 |
| PHASE2 | 18 |
| PHASE1/PHASE2 | 6 |
| PHASE3 | 4 |
| PHASE2/PHASE3 | 2 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT03721341 | PHASE3 | ACTIVE_NOT_RECRUITING | Stereotactic Ablative Radiotherapy for Comprehensive Treatment of 4-10 Oligometastatic Tumors |
| NCT05717166 | PHASE3 | RECRUITING | A Randomized Phase III Trial of Stereotactic Ablative Radiotherapy for Patients With Up to 10 Oligometastases and a Synchronous Primary Tumor. |
| NCT00369785 | PHASE3 | COMPLETED | Donepezil in Treating Patients Who Have Undergone Radiation Therapy for Brain Tumors |
| NCT01861938 | PHASE2/PHASE3 | WITHDRAWN | Modified Melanoma Vaccine for High Risk or Low Residual Disease Patients |
| NCT02492711 | PHASE3 | COMPLETED | Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of HER2+ Metastatic Breast Cancer |
| NCT05665348 | PHASE2/PHASE3 | COMPLETED | Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic Therapy |
| NCT01446744 | PHASE2 | ACTIVE_NOT_RECRUITING | Stereotactic Ablative Radiotherapy for Comprehensive Treatment of Oligometastatic Tumors (SABR-COMET) |
| NCT05103358 | PHASE2 | ACTIVE_NOT_RECRUITING | Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) |
| NCT05617716 | PHASE2 | RECRUITING | Spine Radiosurgery for Symptomatic Metastatic Neoplasms |
| NCT05731271 | PHASE1/PHASE2 | ACTIVE_NOT_RECRUITING | A First-in-Human, Phase 1 Study of TST003 in Subjects With Solid Tumors |
| NCT06165419 | PHASE2 | RECRUITING | Definitive Radiation for High-Risk Spine Metastases |
| NCT06856603 | PHASE2 | RECRUITING | OLIGO-10: Stereotactic Ablative Radiation Therapy for Metastatic Patients With 6 to 10 Metastatic Sites |
| NCT07480928 | PHASE1/PHASE2 | RECRUITING | Dual-Targeting CAR-NK Cells Targeting Mesothelin (MSLN) and MUC1 in Advanced Pancreatic Ductal Adenocarcinoma |
| NCT00480389 | PHASE2 | COMPLETED | Pre-operative Administration of Sorafenib in Patients With Metastatic Renal Cell Carcinoma Undergoing Kidney Removal |
| NCT00532454 | PHASE2 | TERMINATED | Evaluation of the Association Between CYP2D6 Genetic Polymorphisms and the Treatment Effect of Tamoxifen |
| NCT00609401 | PHASE2 | COMPLETED | Study Comparing Association Between Sorafenib and Interleukin-2 (IL-2) Versus Sorafenib in 1st Line Therapy in Advanced (Adv) Renal Cell Carcinoma (RCC) |
| NCT01020305 | PHASE1/PHASE2 | TERMINATED | Temsirolimus to Reverse Androgen Insensitivity for Castration-resistant Prostate Cancer |
| NCT01089595 | PHASE2 | TERMINATED | Trial of Tasigna (Nilotinib) 400 mg Twice Daily Alone or With Gleevec (Imatinib Mesylate) 400 mg Daily for Patients With Advanced Gastrointestinal Stromal Tumor (GIST) |
| NCT01289522 | PHASE2 | COMPLETED | Chemotherapy With Cetuximab in Treating Patients With Recurrent or Metastatic Head and Neck Cancer |
| NCT01450683 | PHASE2 | TERMINATED | Study of Itraconazole in Castrate-resistant Prostate Cancer (CRPC) Post-chemotherapy |
| NCT01484860 | PHASE2 | TERMINATED | Study of AUY922 in Metastatic Pancreatic Cancer Who Are Resistant to First Line Chemotherapy |
| NCT01703910 | PHASE2 | COMPLETED | Study of Individualized Therapies Selection for Patients With Metastatic Colorectal Carcinoma According to the Therapeutic |
| NCT01875380 | PHASE2 | COMPLETED | Regorafenib in Frail and/or Unfit for Chemotherapy Patients With Metastatic Colorectal Cancer |
| NCT02175654 | PHASE2 | TERMINATED | Regorafenib as Single Agent in Patients With Metastatic Colorectal Cancer (mCRC) With Any RAS or BRAF Mutation Previously Treated With FOLFOXIRI Plus Bevacizumab |
| NCT02226289 | PHASE2 | UNKNOWN | Bevacizumab-containing Regimen for Metastatic Colorectal Cancer Failed to Cytotoxic Treatment |
| NCT02856867 | PHASE2 | WITHDRAWN | Nintedanib Plus mFOLFOX6 for Previously Untreated Metastatic Esophagogastric Adenocarcinoma (MEGAN) |
| NCT03705403 | PHASE2 | TERMINATED | IMMUNOtherapy and Stereotactic ABlative Radiotherapy (IMMUNOSABR) a Phase II Study |
| NCT04418661 | PHASE1/PHASE2 | TERMINATED | Safety and Efficacy Study of Vociprotafib (SAR442720) in Combination With Other Agents in Advanced Malignancies |
| NCT05099549 | PHASE1/PHASE2 | TERMINATED | Safety, Tolerability, and Anti-Tumor Activity of AFM24 in Combination With SNK01 in Subjects With Advanced/Metastatic EGFR-Expressing Cancers |
| NCT05390528 | PHASE1/PHASE2 | UNKNOWN | A Study Evaluating the Safety, Tolerability, Pharmacokinetic and Efficacy of HLX301(TIGIT×PDL1 Bispecific) in Locally Advanced/Metastatic Solid Tumors or Lymphoma |
| NCT05518253 | PHASE1 | RECRUITING | A Clinical Study of CD70-targeted CAR-T in the Treatment of CD70-positive Advanced/Metastatic Solid Tumors |
| NCT05678010 | PHASE1 | ACTIVE_NOT_RECRUITING | A Study of AZD1390 and Stereotactic Body Radiotherapy (SBRT) for People With Metastatic Solid Tumor Cancer |
| NCT06383507 | PHASE1 | NOT_YET_RECRUITING | A Clinical Study of Anti-CD70 UCAR-T in Relapsed or Refractory Solid Tumors |
| NCT06586957 | PHASE1 | RECRUITING | A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors |
| NCT07030712 | PHASE1 | RECRUITING | A Clinical Study of MK-8294 in Participants With Advanced Solid Tumors (MK-8294-001) |
| NCT07404332 | PHASE1 | RECRUITING | 5-Azacitidine Plus PD-1/PD-L1 Inhibitor With PD-1/PD-L1 Refractory Tumors |
| NCT00676949 | PHASE1 | COMPLETED | Safety Study of Cancer Specific Epitope Peptides Cocktail for Cervical, GI, and Lung Tumors |
| NCT00678158 | PHASE1 | COMPLETED | Study Using High-Dose Single Fraction Image-Guided Radiotherapy for Metastatic Lesions to Soft Tissue Masses, Lymph Node, or Bone |
| NCT00705497 | PHASE1 | COMPLETED | Radiofrequency Ablation of Tumors |
| NCT01648764 | PHASE1 | COMPLETED | A Study of LY2334737 in Participants With Cancer That is Advanced and/or Has Spread |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| DONEPEZIL | 4 | 3 |
| REGORAFENIB | 4 | 2 |
| ADAGRASIB | 4 | 1 |
| AXATILIMAB | 4 | 1 |
| BICALUTAMIDE | 4 | 1 |
| DALTEPARIN SODIUM | 4 | 1 |
| DAROLUTAMIDE | 4 | 1 |
| IPILIMUMAB | 4 | 1 |
| ITRACONAZOLE | 4 | 1 |
| MARGETUXIMAB | 4 | 1 |
| NILOTINIB | 4 | 1 |
| NINTEDANIB | 4 | 1 |
| SORAFENIB | 4 | 1 |
| TEMSIROLIMUS | 4 | 1 |
| AR-42 | 2 | 1 |
| DARLEUKIN | 2 | 1 |
| JNJ-27548547 | 2 | 1 |
| LUMINESPIB | 2 | 1 |
| TROCULEUCEL | 2 | 1 |
| VOCIPROTAFIB | 2 | 1 |
| AZD-1390 | 1 | 1 |
| LY-2334737 | 1 | 1 |
| CHEMBL4783522 | 0 | 1 |
| CHEMBL4457117 | 0 | 1 |
| CHEMBL4878843 | 0 | 1 |
| CHEMBL5206636 | 0 | 1 |
| HYOSCYAMINE | -1 | 1 |